Global Cancer Research and Control Seminar Series 2025 (Past Webinars)

Past Webinars

 

  Thursday, April 10, 2025 | 10:00 - 11:00am ET


The Changing Global Landscape of National Cancer Control Plans

 

Yannick Romero, Ph.D. Yannick Romero, Ph.D., Senior Knowledge and Advocacy Manager
Union for International Cancer Control

Yannick Romero, Ph.D., is the Senior Knowledge and Advocacy Manager within the Knowledge, Advocacy, and Policy team at the Union for International Cancer Control. Dr. Romero’s work primarily focuses on developing and gathering evidence-based information for global tobacco control. He also leads the Lung Cancer Collaboration Secretariat. Dr. Romero is dedicated to national cancer control planning, analyzing and evaluating countries' cancer plans in the frame of the International Cancer Control Partnership. Over the past decade, Dr. Romero has worked with diverse stakeholders throughout the fields of oncology, communicable diseases, and genetics. He earned his Ph.D. in molecular and cellular biology from the University of Geneva Medical School.

 

Zuzanna Tittenbrun, M.Sc., M.A. Zuzanna Tittenbrun, M.Sc., M.A., Global Resources Manager
Union for International Cancer Control

Zuzanna Tittenbrun, M.Sc., M.A., is a Global Resources Manager with the Knowledge, Advocacy, and Policy team at the Union for International Cancer Control (UICC). Ms. Tittenbrun works in the area of cancer staging, managing UICC’s flagship Tumor, Node, Metastases (TNM) Project, which publishes the TNM Classification of Malignant Tumours. She also works in cancer control planning, managing a web portal for the International Cancer Control Partnership, which serves as a repository of publicly available national cancer control plans. Before joining UICC, Ms. Tittenbrun worked for the Nobel Peace Prize–winning Cluster Munitions Coalition of the International Campaign to Ban Landmines, coordinating civil society’s presence in the humanitarian disarmament arena. She holds a Master of Arts in cultural studies and foreign languages and a Master of Science in global health policy from the London School of Hygiene & Tropical Medicine.

Abstract

The global cancer control landscape continues to change rapidly — seeing progress and challenges in research, treatment, and policy. This seminar will offer a summary of the International Cancer Control Partnership's 2023 global review of national cancer control plans, highlighting the methodology, major findings, and key trends in cancer prevention, early detection, treatment, and survivorship worldwide.
 

  Thursday, November 14, 2024 | 10:00 - 11:00am ET


Tobacco Control in Armenia and Georgia: Research Assessing Strategies for Community Mobilization and Intervention Dissemination

 

Carla Berg, Ph.D., M.B.A. Carla Berg, Ph.D., M.B.A., Professor
George Washington University Milken Institute School of Public Health

Carla J. Berg, Ph.D., M.B.A., is a Professor in the Department of Prevention and Community Health at George Washington University's (GW) Milken Institute School of Public Health and the Associate Center Director for Population Sciences and Policy at the GW Cancer Center. Dr. Berg’s research focuses primarily on socio-structural determinants of health, particularly as they relate to NCD prevention and control and related disparities. In particular, her research examines tobacco and cannabis use in the context of related policies and marketing influences; policy adoption, implementation, and evaluation; and developing and testing scalable interventions to reduce NCD risk and related burdens.

Abstract

In this seminar, Dr. Berg will discuss the execution and results of two NIH-funded studies in Armenia and Georgia, testing 1) the effects of local coalitions to promote smoke-free air policies and compliance in 14 communities; and 2) the adaptation and implementation of an evidence-based smoke-free homes intervention, disseminated via local coalitions and national quit lines. This session will also describe how this research has integrated research capacity building through grants and related training programs focused on non-communicable disease (NCD) prevention in Armenia and Georgia.
 

Presentation Recording 


  Thursday, October 10, 2024 | 10:00 - 11:00am ET


Pathways to Cancer Diagnosis in Southern Africa

 

Jennifer Moodley, M.B.Ch.B., M.Med., Ph.D. Jennifer Moodley, M.B.Ch.B., M.Med., Ph.D., Director, Cancer Research Initiative
University of Cape Town

Jennifer Moodley, M.B.Ch.B., M.Med., Ph.D., is the Director of the Cancer Research Initiative at the University of Cape Town and co-Director of the African aWAreness of CANcer and Early Diagnosis (AWACAN-ED) program. Prof. Moodley is a Public Health Medicine Physician with expertise in health systems research, epidemiology, advocacy, and public policy development. She has worked as a clinician in rural and urban healthcare settings and has first-hand experience of the challenges in providing healthcare in resource-constrained environments. She has been involved in the development and implementation of diverse public health programs and policies; conducted health systems research to support national and provincial public health objectives; and mentored under- and post-graduates to meet similar responsibilities. Prof. Moodley’s research focuses on primary and secondary cancer prevention and improving pathways to cancer diagnosis and care. She values the importance of multi-disciplinary teams in addressing public health issues and is committed to social development and translating research into policy and practice.

Abstract

In this seminar, Professor Moodley will focus on the early recognition and management of individuals with possible cancer symptoms. The presentation will draw on findings from the African Women Awareness of Cancer (AWACAN) project and AWACAN-ED program.
 

Presentation Recording 


  Thursday, August 8, 2024 | 10:00 - 11:00am ET


Cancer Prevention and Control in Mexico: Epidemiologic Research and Program Implementation

 

Martin Lajous, M.D., Sc.D. Martin Lajous, M.D., Sc.D., Faculty-Researcher
Instituto Nacional de Salud Pública

Martin Lajous, M.D., Sc.D., is a medical doctor and cancer epidemiologist at the National Institute of Public Health (INSP) in Mexico. Dr. Lajous received his medical degree from the National Autonomous University of Mexico and Master’s and Doctoral degrees in epidemiology from the Harvard T.H. Chan School of Public Health. Dr. Lajous acts as a Faculty-Researcher at INSP in Mexico since his appointment in 2004. In addition, he is an adjunct professor at the Harvard T.H. Chan School of Public Health. At INSP he helped design and develop the Mexican Teachers’ Cohort (MTC) and now serves as its principal investigator. MTC has since become part of the U.S. National Cancer Institute’s (NCI) Cancer Cohort Consortium. Dr. Lajous teaches courses at INSP on cancer epidemiology, causal inference (methodologies and strategies that allow researchers to draw causal conclusions based on data), and implementation science. His research interests are cancer epidemiology and implementation of cancer prevention and control programs.

Abstract

In this seminar, Dr. Lajous will review how researchers at INSP, as well as other institutions in Mexico, are tackling the burden of gynecologic, breast, colorectal, and liver cancers through epidemiologic research and program development.
 

Presentation Recording 


  Tuesday, June 18, 2024 | 10:00 - 11:00am ET


CAR T-Cell Therapy Development in India

 

Gaurav Narula, M.D., D.N.B. Gaurav Narula, M.D., D.N.B., Professor of Pediatric Oncology & Health Sciences
Tata Memorial Centre

Gaurav Narula, M.D., D.N.B., is a Professor of Pediatric Oncology & Health Sciences at the Tata Memorial Centre (TMC) and Homi Bhabha National Institute in Mumbai. He graduated from the Armed Forces Medical College in Pune in 1987, and later completed his M.D. in pediatrics from the same institution in 1995. Followed by a Fellowship in hematology oncology from Tata Memorial Hospital in 2003. A veteran of the Indian Navy, Dr. (Surgeon Commander) Narula, served for 25 years as a Medical Officer in various Naval ships and hospitals. In 2012, he retired as Professor of Pediatrics & Hematology at INHS Asvini—the Apex referral multi-specialty hospital of the Indian Navy—and joined Tata Memorial Centre in his current appointment. Dr. Narula was convener of the Pediatric Hematolymphoid Group at TMC from 2015-18. This group manages more than 1,200 new cases of children with blood and lymphoid cancers every year. His interests are in immunotherapy and collaborative clinical trials for acute lymphoblastic leukemia (ALL), Hodgkin lymphoma & histiocytosis. He was principal investigator and part of the core team for ICiCLe 1 and 2—collaborative multi-center randomized clinical trials for childhood ALL. He is also Study Chair for a nation-wide multi-center randomized clinical trial in Pediatric Hodgkin lymphoma. Since 2015, Dr. Narula has been collaborating with IIT-B at Mumbai to develop the first CAR T product in India, which is now approved by the Central Drugs Standard Control Organization to ImmunoACT. He was a member of the Clinical Advisory Group for the WHO Classification of Hematolymphoid Tumors (2022) and a co-author in the chapter on histiocytic disorders. He founded the Immuno-Oncology Society of India and serves as Treasurer. Dr. Narula was also the Founder of the Pediatric Hematology Oncology Journal (PHOJ)—the official journal of the PHO Chapter of Indian Academy of Pediatrics and was Editor-in-Chief from its inception in 2015, until 2021.

 

Hasmukh Jain, M.D., D.M. Hasmukh Jain, M.D., D.M., Medical Oncologist
Tata Memorial Hospital

Hasmukh Jain, M.D., D.M., is a Medical Oncologist in the Adult Hematolymphoid and Cell Therapy Unit at Tata Memorial Hospital. Dr. Jain obtained a M.D. in general medicine from Kasturba Medical College and D.M. in medical oncology from Tata Memorial Centre. His primary research focus is acute lymphoblastic leukemia (ALL), Hodgkin lymphoma, cell therapy, and supportive care. He is a clinical primary investigator (PI) on several investigator-initiated trials and was the PI on the clinical trials that led to approval of the first CAR T-cell therapy product in India, in October 2023. His group is now working on ways to improve access of CAR T-cell therapy to Indian patients. Dr. Jain has taken part in numerous national and international conferences as a speaker and expert panelist.

Abstract

In this seminar, Drs. Narula and Jain will discuss the initiation and development of India's first CAR T-cell program. Drs. Narula and Jain will cover early collaboration with the National Cancer Institute, development and results of the pediatric and adult trials, and commercial approval and roll-out.
 

Presentation Recording 


  Thursday, April 11, 2024 | 10:00 - 11:00am ET


Colorectal Cancer Screening, Biology, and Treatment in Nigeria

 

Isaac Alatise, M.D. Isaac Alatise, M.D., Professor of Surgery
Obafemi Awolowo University

Isaac Alatise, M.D., is a Professor of Surgery in the College of Health Sciences at Obafemi Awolowo University (OAU) in Nigeria, he also acts as a Consultant General Surgeon at the OAU Teaching Hospital. He trained in surgical oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Alatise is a leader in surgical oncology and gastroenterology in Nigeria and has trained over thirty general surgeons interested in surgical oncology. He holds multiple positions in various cancer organizations and associations including—Secretary General of the Society of Gastroenterology and Hepatology in Nigeria; Secretary General of the Nigeria Chapter of the International Hepatopancreatobiliary Association; Vice President (West Africa) of the African Organisation for Research and Training in Cancer; Membership on the American Society of Clinical Oncology African Regional Council; and Membership on The Lancet Oncology Commission on Global Cancer Surgery. In 2016, Dr. Alatise was selected as one of the “50 for 50” future cancer research leaders by the International Agency for Research on Cancer. He was awarded the prestigious Professor T.A.I. Grillo ‘Excellence in Research’ Award (2017) and a ‘Excellence in Grantsmanship’ award (2023) by Obafemi Awolowo University in recognition of his work. He has over 170 peer-reviewed publications and four book chapters.

 

Peter Kingham, M.D. Peter Kingham, M.D., Director, Global Cancer Disparity Initiatives
Memorial Sloan Kettering Cancer Center

Peter Kingham, M.D., obtained his undergraduate degree from Yale University and M.D. from SUNY Stony Brook Medical School. He completed his general surgery residency at New York University before he undertook a research fellowship in hepatic immunology in the DeMatteo Laboratory at Memorial Sloan Kettering (MSK) Cancer Center in New York. After finishing residency, Dr. Kingham completed a two-year fellowship in surgical oncology at MSK prior to being appointed on the Hepatopancreatobiliary Service. Dr. Kingham acts as Director of the International Surgical Oncology Fellowship and the Global Oncology Fellowship. In 2015, he was appointed Director of Global Cancer Disparity Initiatives. In 2022, he was promoted to Professor. Dr Kingham’s primary research interest is determining how to improve cancer care for patients in low- and middle-income countries and colorectal cancer liver metastasis management. He has over 300 publications in peer-reviewed journals and authored 18 chapters.

Abstract

In this seminar, Professor Olusegun Isaac Alatise and Dr. Peter Kingham discuss their research in colorectal cancer screening, biology, and treatment in Nigeria. Drs. Alatise and Kingham have conducted multiple prospective studies on cancer in Nigeria. Together they received a D43 grant in support of expanding cancer research capacity in Nigeria using team science. Drs. Alatise and Kingham also co-founded the African Research Group for Oncology (ARGO) in 2013, which runs a clinical database and biobank for colorectal and breast cancer.
 

Presentation Recording